Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.

Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.

The present invention relates to a novel benzene derivative and immunosuppressive-related use thereof. Specifically, it relates to a composition comprising a compound of Formula 1, its stereoisomer, solvate, hydrate, crystalline form, or pharmaceutically acceptable salt. The composition has preventive or therapeutic applications in immune disorders such as autoimmune diseases, transplant rejections, allergic diseases, and inflammatory conditions.

The present invention relates to a novel benzene derivative and immunosuppressive-related use thereof. Specifically, it relates to a composition comprising a compound of Formula 1, its stereoisomer, solvate, hydrate, crystalline form, or pharmaceutically acceptable salt. The composition has preventive or therapeutic applications in immune disorders such as autoimmune diseases, transplant rejections, allergic diseases, and inflammatory conditions.

A compound of formula (Ie): ##STR00001##
wherein Y.sup.1 represents an aryl group, X.sup.2 represents a O group, a NH group, a S group, a CONH group, a NHCONH group, a NHCO group, a CH(OH) group, a CH(COOH)NH group, a CH(COOCH.sub.3)NH group, a C(OH)(CH.sub.2OH), a ##STR00002##
group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a SO.sub.2 group, or a SO.sub.2NH group, Y.sup.2 represents a hydrogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a CHC(OH).sub.2, a COOR.sub.f, wherein R.sub.f represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, a morpholinyl group, a dihydropyranyl group, a ##STR00003##
group, a ##STR00004##
group, a PO(OR.sub.f)(OR.sub.f) group, wherein R.sub.f and R.sub.f independently represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, an oxetanyl group, a Si(CH.sub.3).sub.3 group, a NHCOO(C.sub.1-C.sub.4)alkyl group, or a CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

A compound of formula (Ie): ##STR00001##
wherein Y.sup.1 represents an aryl group, X.sup.2 represents a O group, a NH group, a S group, a CONH group, a NHCONH group, a NHCO group, a CH(OH) group, a CH(COOH)NH group, a CH(COOCH.sub.3)NH group, a C(OH)(CH.sub.2OH), a ##STR00002##
group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a SO.sub.2 group, or a SO.sub.2NH group, Y.sup.2 represents a hydrogen atom, a hydroxyl group, a (C.sub.1-C.sub.4)alkoxy group, a CHC(OH).sub.2, a COOR.sub.f, wherein R.sub.f represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, a morpholinyl group, a dihydropyranyl group, a ##STR00003##
group, a ##STR00004##
group, a PO(OR.sub.f)(OR.sub.f) group, wherein R.sub.f and R.sub.f independently represents a hydrogen atom or a (C.sub.1-C.sub.4)alkyl group, an oxetanyl group, a Si(CH.sub.3).sub.3 group, a NHCOO(C.sub.1-C.sub.4)alkyl group, or a CR.sup.1R.sup.2R.sup.3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.

The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.

Disclosed is a pharmaceutical composition for preventing or treating a mental disorder. More specifically, disclosed is a pharmaceutical composition for treating or preventing a mental disorder, including substance-related and addictive disorder, depressive disorder, anxiety disorder, or post-traumatic stress disorder, by using a compound that simultaneously regulates mGluR5 and 5-HT.sub.2AR.

Disclosed is a pharmaceutical composition for preventing or treating a mental disorder. More specifically, disclosed is a pharmaceutical composition for treating or preventing a mental disorder, including substance-related and addictive disorder, depressive disorder, anxiety disorder, or post-traumatic stress disorder, by using a compound that simultaneously regulates mGluR5 and 5-HT.sub.2AR.